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Two carriers of human T-cell lymphotropic virus type I (HTLV-I) with interstitial
pneumonia are described.  The first case, a 60-year-old man, was admitted with cough
and dyspnea on exertion.  Light microscopy of a lung specimen obtained by a trans-
bronchial lung biopsy (TBLB ) showed thickening of the alveolar walls with infiltration
of lymphocytes and fibrosis of the pulmonary parenchyma.  Immunohistochemical analy-
sis of the TBLB specimen showed positive staining in the lymphocytes for UCHL-1.
This case was suspected as HTLV-I associated bronchiolo-alveolar disorder.  The second
case, a 74-year-old man, visited our hospital because of a persistent productive cough
and dyspnea on exertion.  Light microscopy of the TBLB showed a slight thickening of
the alveolar walls and fibrosis of the pulmonary parenchyma with minimal infiltration
of lymphocytes.  Only 2.2% of the bronchoalveolar lavage fluid consisted of lymphocytes.
The findings of the second case suggest that some factors other than T-lymphocytes
may be related with the development of interstitial pneumonia in HTLV-I carriers.
Interstitial pneumonia in HTLV-I carriers may be caused by as yet undiscovered mecha-
nisms.  A cohort study involving residents of an area where HTLV-I is endemic should
be conducted to clarify the mechanism of pulmonary involvement in HTLV-I carriers.
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Human T-cell lymphotropic virus type I (HTLV-
I) is an oncogenic retrovirus.  HTLV-I is endem-
ic in the southwestern region of Japan.  Most
HTLV-I infected subjects are non-symptomatic
carriers.  HTLV-I has been implicated in the
development of such diseases as HTLV-I asso-
ciated myelopathy (HAM) (Roman and Osame,
1988), HTLV-I associated bronchiolo-alveolar
disorder (HABA) (Kimura, 1992) [also called
as HTLV-I associated bronchopneumopathy
(HAB) (Maruyama et al., 1988)], autoimmune
thyroiditis (Akamine et al., 1996) and HTLV-I
associated uveitis (Mochizuki et al., 1992).
Inflammatory disorders can occur in the carrier
state in HTLV-I infected individuals without
adult T-cell leukemia-lymphoma (ATLL).  We
report two carriers of HTLV-I who exhibited
interstitial pneumonia.




A 60-year-old Japanese man, a resident of Oki
Island in Shimane Prefecture, was admitted to
our hospital in March 1991 because of cough
and dyspnea on exertion.  He smoked 60 ciga-
rettes daily for 30 years but quit smoking 2
years prior to admission.  Auscultation of the
lungs revealed fine crackles in both lower lung
fields.  Laboratory data showed an elevated
white blood cell count (11,300/mm3; segmental
neutrophils 44%, band neutrophils 4%, lympho-
cytes 35%, monocytes 7%, eosinophils 10%)
and lactic acid dehydrogenase (LDH; 257 IU/
L).  Atypical lymphocytes were not detected in
peripheral blood.  Arterial blood gas analysis
showed hypoxemia (PaO2; 67 mmHg).  He
tested negative for hepatitis C
virus antibody, rheumatoid factor
and anti-nuclear antibody.  HTLV-
I antibody was positive (2560-
fold).  Bronchoalveolar lavage
(BAL) was performed in the right
B4 (Table 1).  Although the total
cell count in the BAL fluid was
elevated, the ratio of lymphocytes
was within the normal range (The
BAL Cooperative Group Steering
Committee, 1990).  Spirography
revealed a decreased vital capacity
(VC) and a restrictive pattern (%VC,
68.4%).  The pulmonary diffusing ca-
pacity for carbon monoxide (DLco)
was decreased (%DLco, 59.3%).
Computed tomography of the chest
demonstrated bilateral reticulo-
nodular and honey-combed shadows
in the lung fields (Fig.1).  Light mi-
croscopy of the transbronchial lung
biopsy (TBLB) specimen showed thickening of
the alveolar walls  with infi l trat ion of
lymphocytes and fibrosis of the pulmonary
parenchyma.  No atypical lymphocytes were
detected in the infiltrating cells.  Immunohisto-
chemical analysis of the TBLB specimen show-
ed positive staining of lymphocytes for UCHL-
1 (Nichirei Co., Tokyo, Japan) by the strepto-
avidin-biotin method [HISTOFINE SAB-
PO(MULTI) KIT, Nichirei Co.] (Fig. 2).
This patient developed interstitial pneumo-
nia and died in December 1992.  The autopsy
revealed the following: the lung—diffuse
honey-combed lungs, usual interstitial pneumo-
nia (UIP) and acute bronchopneumonia; the
heart—hypertrophy of the heart; the pancreas—
chronic pancreatitis; the thyroid—adenomatous
goiter; the bone marrow—no atypical findings
in the bone marrow; the lymph nodes—no
atypical lymphocytes in the lymph nodes.
Table 1.  Results of bronchoalveolar lavage
           Case 1    Case 2
Total cell count (106/dL) 23.0 66.0
Cell differentiation Macrophages (%) 86.0 97.6
Lymphocytes (%) 10.0 2.2
Neutrophils (%) 1.2 0.2
Eosinophils (%) 2.6 0
Basophils (%) 0.2 0
Lymphocytes subset CD3 (%) 39.6 83.4
CD4 (%) 24.7 60.8
CD8 (%) 19.3 16.4
CD4/CD8 1.3 3.7
Fig. 1.  Computed tomography of the
chest in case 1.
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Case 2
A 74-year-old Japanese man who lived in
Yonago city in Tottori Prefecture visited our
hospital in October 1995 because of a persistent
productive cough, and dyspnea on exertion.  He
had stopped smoking 20 years previously, but
until then, he had smoked 40 cigarettes daily for
about 35 years.  Abnormal findings on a chest
radiograph were detected when he was about 60
years old.  Chest auscultation revealed fine crack-
les in both lower lung fields.  Laboratory data
revealed an increased erythrocyte sedimenta-
tion rate (70 mm/h), but normal hematological
findings (white blood cell count; 8900/mm3;
segmental neutrophils 64%, band neutrophils
2%, lymphocytes 25%, monocytes 9%).  No
atypical lymphocytes were found in the peri-
pheral blood. Serum LDH was within the nor-
mal range (190 IU/L).  Analysis of arterial blood
gas showed hypoxemia (PaO2;71 mmHg).  The
patient tested negative for hepatitis C virus
antibody, rheumatoid factor and antinuclear
antibody.  HTLV-I antibody was positive
(32,000-fold).  Serum soluble interleukin-2
receptors (sIL-2R) were elevated (784 U/mL),
but those in the BAL fluid were not (< 85 U/
mL).  BAL was performed in the right B4 (Table
1).  Although the total cell count in the BAL
fluid was markedly elevated, only a low percent
(2.2%) was lymphocytes.  Pulmonary function
testing demonstrated a restrictive pattern of
disturbance (%VC, 54%) with a decreased DLco
(%DLco, 61%).  Computed tomography of the
chest demonstrated bilateral reticulo-nodular
and honey-combed shadows in the lung fields
(Fig. 3).  Light microscopy of the TBLB speci-
men showed a slight thickening of the alveolar
walls and fibrosis of the pulmonary paren-
chyma with minimal infiltration by lympho-
cytes.  No atypical lymphocytes were detected
in the infiltrating cells.  Immunohistochemical
analysis of the TBLB specimen showed partly
positive staining of lymphocytes for UCHL-1
(Fig. 4).
To detect the HTLV-I provirus in the pe-
ripheral blood lymphocytes of this patient, we
examined the separated peripheral blood mono-
Fig. 2.  Immunohistochemical staining of the specimen obtained from TBLB.  Positive reactions of
infiltrating lymphocytes for UCHL-1 are shown.  × 100.
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nuclear cells (PBMCs).  The
PBMCs were incubated for 15
min at 70˚C with 1 mL of cell
lysis buffer that  consisted of 10
mM Tris-HCl, pH 7.5/10 mM
EDTA, 1% sodium dodecyl sul-
fate and protease K.  Protease K
was added once more and the solu-
tion was incubated overnight at
37˚C.  Total cellular DNA was ex-
tracted according to the phenol-
chloroform method.  The poly-
merase chain reaction (PCR) was
performed by using the primers
designed to amplify a 159-base
pair (bp) segment in the pX re-
gion of HTLV-I (Seiki et al.,
1983) (5'-CGGATACCCAGTCTACGTGT
and 5'-GAGCCGATAACGCGTCCATCG,
respectively) (Hatanaka and Kawanishi, 1990).
Sample DNA (1 µg) was denatured at 95˚C,
after which PCR was performed by step cycle at
94˚C for 20 s, at 50˚C for 30 s, and at 72˚C for
30 s for a total of 35 cycles.  The amplified product
was electrophoresed in 3% agarose gel and
Fig. 4.  Immunohistochemical staining of the specimen obtained from TBLB.  Positive reactions of a few
infiltrating lymphocytes for UCHL-1 are shown.  × 100.
Fig. 3.  Computed tomography of the chest in case 2.
transferred to Hybond N+ (Amersham Japan
Co., Ltd., Tokyo, Japan).  A 25-base oligo-
nucleotide probe (5'-TACTGGCCACCTGTC
CAGAGCATCA) that hybridized to an inter-
vening sequence between two primers of
HTLV-I was labeled with horseradish peroxy-
dase by using ECL direct nucleic acid labeling
and a detection system (Amersham Japan).
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Results of PCR-Southern analysis of this pa-
tient are shown in Fig. 5.  A markedly amplified
and hybridized product was detected.
Discussion
The incidence of pulmonary complications is
markedly higher in ATLL than in other hemato-
logical malignancies (Yoshioka et al., 1985).
However, most of the HTLV-I infected subjects
are non-symptomatic carriers.  Even so, HTLV-I
is implicated as a cause of such inflammatory
disorders as HABA (Kimura, 1992) [or HAB
(Maruyama et al., 1988)].  The pulmonary in-
volvement seen in HABA (HAB) is mainly man-
ifested as interstitial pneumonia (Maruyama et al.,
1988; Setoguchi et al., 1991; Kimura, 1992) or
a diffuse panbronchiolitis-like lesion (Kimura,
1992; Mukae et al., 1994; Kikuchi et al., 1996).
The mechanism of pulmonary involvement
with HTLV-I remains unclear.  Salahuddin and
coworkers (1984) reported that T-cells trans-
formed in vitro by HTLV-I acquired the ability
to release a considerable number of biologic
response modifiers.  Recent reports show that T-
lymphocyte alveolitis is common in the chronic
spastic myelopathy that is associated with
HTLV-I infection (Sugimoto et al., 1987;
Vernant et al., 1988).  Sugimoto and coworkers
(1989) reported that sIL-2R was increased in
the BAL fluid of HAM patients, and suggested
that the increased T-lymphocytes in the lung
were activated locally to produce sIL-2R.
Therefore, immune mechanisms may be im-
portant in the development of pulmonary le-
sions.  The activation of T-lymphocytes by the
HTLV-I tax gene may trigger an effect in the
immune system (Tanaka et al., 1990).  Maruyama
and colleagues (1988, 1989, 1992) reported that
HAB seemed to occur in healthy carriers as well
as in patients with HAM.  CD4+ lymphocytes
and the ratio of CD4/CD8 were increased in the
BAL fluid of these patients.  These investi-
gators also reported a high rate of T cells infil-
tration in the lung specimens.
We encountered two HTLV-I carriers with
pulmonary involvement.  Case 1 died from
Fig. 5.  PCR-Southern analysis of HTLV-I provirus
in peripheral blood lymphocytes of the patient in
case 2.  Lane 1, case 2; Lane 2, a HAM patient who
is an HTLV-I carrier; Lane 3, an idiopathic inter-
stitial pneumonia patient without HTLV-I; Lane 4,
an HTLV-I carrier.
developed interstitial pneumonia in December
1992.  The autopsy revealed that this patient
was an HTLV-I carrier.  In case 2, no atypical
lymphocytes were detected in the peripheral
blood.  Since the HTLV-I provirus was detected
in his peripheral blood by PCR (Fig. 5), we be-
lieve that case 2 was also a carrier of HTLV-I.
The chest radiograph findings and histo-
logical analysis in case 1 suggested a diagnosis
of UIP.  The total cell count in his BAL fluid
was elevated compared with that of healthy ex-
smokers (The BAL Cooperative Group Steer-
ing Committee, 1990).  The infiltrative lympho-
cytes in the lung showed positive staining for
UCHL-1 on immunohistochemical analysis
(Fig. 2).  UCHL-1 recognizes specifically the
180 kD low molecular weight isoform of
CD45RO or leukocyte common antigen family
(Terry et al., 1988).  UCHL-1 labels most of the
thymocytes, a subpopulation of resting T cells
within both the CD4 and CD8 subsets, and the
mature activated T cells.  Although cells of the
myelomonocytic series are also labeled by
UCHL-1, normal B cells or NK cells are consis-
tently negative (Smith et al., 1986).  The
UCHL-1-positive infiltrating lymphocytes
were thought to be mainly T-cells in this case.
We suspected that case 1 was HABA in broad
sense, which has been reported (Kimura, 1992).
The histological findings in case 2 revealed
fibrosis of pulmonary parenchyma and minimal
infiltration of lymphocytes that stained partly
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positive for UCHL-1 (Fig.4).  The total cell
count of BAL fluid was markedly elevated, but
the percentage of lymphocytes was low (2.2%)
compared with that of healthy ex-smokers (The
BAL Cooperative Group Steering Committee,
1990).  The value of sIL-2 in the BAL fluid was
not elevated. These findings differ from those
of previous reports (Maruyama et al., 1988,
1989, 1992), and suggest that undetermined
mechanisms may cause interstitial pneumonia
in this HTLV-I carrier.  Although the mecha-
nism is unclear, activated alveolar macrophages
may have played an important role in the
development of pulmonary fibrosis (Martinet et
al., 1987) in case 2, as suggested by the marked
increase in the total count of alveolar macro-
phages in his BAL fluid.  Abnormalities shown
on the chest radiograph in this case had been
pointed out at least 14 years previously, demon-
strating that long-term survival of HTLV-I
carriers with interstitial pneumonia is possible.
A cohort study involving residents of a region
where HTLV-I is endemic will be needed to
clarify the mechanism of pulmonary involve-
ment in carriers of HTLV-I.
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